Maurice M. Morelock
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maurice M. Morelock.
Journal of Biomolecular Screening | 2007
Mohammed A. Kashem; Richard M. Nelson; Jeffrey David Yingling; Steven S. Pullen; Anthony S. Prokopowicz; Jessi Wildeson Jones; John P. Wolak; George R. Rogers; Maurice M. Morelock; Roger J. Snow; Carol Ann Homon; Scott Jakes
Numerous assay methods have been developed to identify small-molecule effectors of protein kinases, but no single method can be applied to all isolated kinases. The authors developed a set of 3 high-throughput screening (HTS)–compatible biochemical assays that can measure 3 mechanistically distinct properties of a kinase active site, with the goal that at least 1 of the 3 would be applicable to any kinase selected as a target for drug discovery efforts. Two assays measure catalytically active enzyme: A dissociation-enhanced lanthanide fluoroimmuno assay (DELFIA) uses an antibody to quantitate the generation of phosphorylated substrate; a second assay uses luciferase to measure the consumption of adenosine triphosphate (ATP) during either phosphoryl-transfer to a peptide substrate or to water (intrinsic ATPase activity). A third assay, which is not dependent on a catalytically active enzyme, measures the competition for binding to kinase between an inhibitor and a fluorescent ATP binding site probe. To evaluate the suitability of these assays for drug discovery, the authors compared their ability to identify inhibitors of a nonreceptor protein tyrosine kinase from the Tec family, interleukin-2-inducible T cell kinase (ITK). The 3 assays agreed on 57% of the combined confirmed hit set identified from screening a 10,208-compound library enriched with known kinase inhibitors and molecules that were structurally similar. Among the 3 assays, the one measuring intrinsic ATPase activity produced the largest number of unique hits, the fewest unique misses, and the most comprehensive hit set, missing only 2.7% of the confirmed inhibitors identified by the other 2 assays combined. Based on these data, all 3 assay formats are viable for screening and together provide greater options for assay design depending on the targeted kinase.
Microcirculation | 2011
Paul R. Clark; Todd J. Jensen; Martin S. Kluger; Maurice M. Morelock; Adedayo Hanidu; Zhenhao Qi; Revati J. Tatake; Jordan S. Pober
Please cite this paper as: Clark, Jensen, Kluger, Morelock, Hanidu, Qi, Tatake, Pober (2011). MEK5 is Activated by Shear Stress, Activates ERK5 and Induces KLF4 to Modulate TNF Responses in Human Dermal Microvascular Endothelial Cells. Microcirculation18(2), 102–117.
Journal of Leukocyte Biology | 1996
Mark E. Labadia; Richard H. Ingraham; Josephine Schembri-King; Maurice M. Morelock; Scott Jakes
The chains of the T cell receptor complex play a critical role in the initiation of proximal signaling events upon T cell activation. Three pairs of potential tyrosine phosphorylation sites are located within the cytoplasmic domains of the chains. Subsequent to engagement of the T cell receptor, one or more of these tyrosine residues is phosphorylated. The phosphotyrosine residues, along with flanking amino acids, form an activation motif (and are shared by signaling subunits in the TCR, B cell receptor, and FcγRI) termed tyrosine‐based activation motifs (ITAMs). ITAMs serve as binding sites for SH2 domain‐containing proteins. Recent evidence suggests that the chains provide docking space for several key signal transduction molecules such as ZAP‐70, p56 lck, and Shc. To determine if ZAP‐70, p56 lck, and Shc bind to particular chain ITAM sequences, quantitative free‐solution measurements of binding affinities (Kd) were obtained by use of surface plasmon resonance technology. The results indicate that binding affinities of distinct SH2 domains to individual and paired phosphorylation sites greatly differ, and may dictate the sequence of signal transduction events.
Biochemical Pharmacology | 2009
Lore M. Gruenbaum; Racheline Schwartz; Joseph R. Woska; Rodney P. DeLeon; Gregory W. Peet; Thomas C. Warren; Alison Capolino; Lisa Mara; Maurice M. Morelock; Anthony Shrutkowski; Jessi Wildeson Jones; Christopher Pargellis
The characterization of the potent p38 inhibitor BIRB796 as a dual inhibitor of p38/Jun N-terminal kinases (JNK) mitogen-activated protein kinases (EC 2.7.11.24) has complicated the interpretation of its reported anti-inflammatory activity. To better understand the contribution of JNK2 inhibition to the anti-inflammatory activities of BIRB796, we explored the relationship between the effects of BIRB796 and analogues on cytokine production and on cellular p38 and JNK signaling. We determined the binding affinity for BIRB796 and structural analogues to p38alpha and JNK2 and characterized compound 2 as a p38 inhibitor that binds to p38alpha with an affinity equivalent to BIRB796 but does not bind to any of the JNK isoforms. High-content imaging enabled us to show that the inhibition of p38 signaling by BIRB796 and analogues correlates with the ability of these compounds to inhibit the lipopolysaccharide (LPS)-induced TNF-alpha production in THP-1 monocytes. This finding was extended to cytokine release by disease-relevant human primary cells: to the production of TNF-alpha by peripheral blood mononuclear cells, and of IL-8 by neutrophils. Furthermore, BIRB796 and compound 2 inhibited the production of TNF-alpha in THP-1 monocytes and the IL-12/IL-18-induced production of interferon-gamma in human T-cells with similar potencies. In contrast, cellular JNK signaling in response to cytokines or stress stimuli was only weakly inhibited by BIRB796 and analogues and not affected by compound 2. In summary, our data suggest that p38 inhibition alone is sufficient to completely suppress cytokine production and that the added inhibition of JNK2 does not significantly contribute to the effects of BIRB796 on cytokine production.
Bioorganic & Medicinal Chemistry | 2003
Charles L. Cywin; Raymond A. Firestone; Daniel W. McNeil; Christine A. Grygon; Kathryn M Crane; Della White; Peter R Kinkade; Jerry L. Hopkins; Walter Davidson; Mark E. Labadia; Jessi Wildeson; Maurice M. Morelock; Jeffrey D Peterson; Ernest L. Raymond; Maryanne L. Brown; Denice M. Spero
The design and synthesis of dipeptidyl disulfides and dipeptidyl benzoylhydrazones as selective inhibitors of the cysteine protease Cathepsin S are described. These inhibitors were expected to form a slowly reversible covalent adduct of the active site cysteine of Cathepsin S. Formation of the initial adduct was confirmed by mass spectral analysis. The nature and mechanism of these adducts was explored. Kinetic analysis of the benzoyl hydrazones indicate that these inhibitors are acting as irreversible inhibitors of Cathepsin S. Additionally, the benzoylhydrazones were shown to be potent inhibitors of Cathepsin S processing of Class II associated invariant peptide both in vitro and in vivo.
Journal of Immunology | 1998
Mark E. Labadia; Deborah D. Jeanfavre; Gary O. Caviness; Maurice M. Morelock
Journal of Medicinal Chemistry | 1995
Maurice M. Morelock; R. H. Ingraham; Rajashehar Betageri; Scott Jakes
Journal of Immunology | 1996
Joseph R. Woska; Maurice M. Morelock; Deborah D. Jeanfavre; Barbara-Jean Bormann
Journal of the American Chemical Society | 1999
Pierre R. Bonneau; Firoz Hasani; Céline Plouffe; Eric Malenfant; Steve R. LaPlante; Ingrid Guse; William W. Ogilvie; Raymond Plante; Walter Davidson; Jerry L. Hopkins; Maurice M. Morelock; and Michael G. Cordingley; Robert Deziel
Journal of Pharmaceutical Sciences | 1994
Maurice M. Morelock; Louisa L. Choi; Gerald L. Bell; James L. Wright